tradingkey.logo
搜索

Evolus Inc

EOLS
添加自选
6.900USD
+0.160+2.37%
收盘 07/02, 13:00美东报价延迟15分钟
454.29M总市值
亏损市盈率 TTM

Evolus Inc

6.900
+0.160+2.37%
查看详细走势图
TradingKey 图表
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+2.37%

5天

-3.23%

1月

+4.55%

6月

+2.68%

今年开始到现在

+3.76%

1年

-25.57%

关键数据
6.770今开
6.905最高
534.87K成交量
亏损市盈率 TTM
28.01市盈率动
--股息TTM
0.81%换手率
6.740昨收
6.695最低
2.45M成交额
亏损市盈率静
-15.78市净率
0.00%股息率 TTM
-20.01%ROA
10.62052周最高
1.01量比
-50.42M净利润
65.84M总股本
-0.6682每股收益TTM
1.34Beta
-18729.61%ROE
3.86052周最低
3.12%振幅
64.27%毛利率
454.29M总市值
0.65回报/风险
3.27%风险率

TradingKey Evolus Inc股票评分

单位: USD 更新时间: 2026-07-02

操作建议

Evolus Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在药品行业排名46/157位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价14.67。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Evolus Inc评分

相关信息

行业排名
46 / 157
全市场排名
104 / 4565
所属行业
药品

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看空

Evolus Inc亮点

亮点风险
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
业绩高增长
公司营业收入稳步增长,连续3年增长47.05%
估值合理
公司最新PE估值-10.33,处于3年历史合理位
机构减仓
最新机构持股50.03M股,环比减少24.26%

分析师目标

根据 7 位分析师
买入
评级
14.667
目标均价
+117.61%
涨幅空间

Evolus Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Evolus Inc简介

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
公司代码EOLS
公司Evolus Inc
CEOMoatazedi (David)
网址https://www.evolus.com/

常见问题

Evolus Inc(EOLS)的当前股价是多少?

Evolus Inc(EOLS)的当前股价是 6.90。

Evolus Inc的股票代码是什么?

Evolus Inc的股票代码是EOLS。

Evolus Inc股票的52周最高点是多少?

Evolus Inc股票的52周最高点是10.62。

Evolus Inc股票的52周最低点是多少?

Evolus Inc股票的52周最低点是3.86。

Evolus Inc的市值是多少?

Evolus Inc的市值是454.29M。

现在Evolus Inc(EOLS)的股票是买入、持有还是卖出?

根据分析师评级,Evolus Inc(EOLS)的总体评级为买入,目标价格为14.67。

Evolus Inc(EOLS)股票的每股收益(EPS TTM)是多少

Evolus Inc(EOLS)股票的每股收益(EPS TTM)是-0.80。